Annual EBITDA
$99.96 M
+$10.78 M+12.09%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual earnings before interest, taxes, depreciation & amortization is currently $99.96 million, with the most recent change of +$10.78 million (+12.09%) on 31 December 2023. During the last 3 years, it has risen by +$43.29 million (+76.38%). LGND annual EBITDA is now -88.59% below its all-time high of $876.12 million, reached on 31 December 2019.LGND EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$19.21 M
+$74.48 M+134.76%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly earnings before interest, taxes, depreciation & amortization is currently $19.21 million, with the most recent change of +$74.48 million (+134.76%) on 30 September 2024. Over the past year, it has increased by +$23.12 million (+592.01%). LGND quarterly EBITDA is now -97.76% below its all-time high of $857.90 million, reached on 31 March 2019.LGND Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$112.45 M
+$23.12 M+25.88%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM earnings before interest, taxes, depreciation & amortization is currently $112.45 million, with the most recent change of +$23.12 million (+25.88%) on 30 September 2024. Over the past year, it has increased by +$2.61 million (+2.38%). LGND TTM EBITDA is now -89.12% below its all-time high of $1.03 billion, reached on 31 March 2019.LGND TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.1% | +592.0% | +2.4% |
| 3 y3 years | +76.4% | -40.5% | -20.7% |
| 5 y5 years | -57.9% | +923.2% | -86.3% |
LGND EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -30.0% | +76.4% | -84.3% | +134.8% | -28.6% | +26.4% |
| 5 y | 5 years | -88.6% | +76.4% | -84.3% | +134.8% | -87.2% | +4017.4% |
| alltime | all time | -88.6% | +203.8% | -97.8% | +126.3% | -89.1% | +218.3% |
Ligand Pharmaceuticals Incorporated EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $19.21 M(-134.8%) | $112.45 M(+25.9%) |
| June 2024 | - | -$55.27 M(-145.2%) | $89.33 M(-43.3%) |
| Mar 2024 | - | $122.35 M(+367.9%) | $157.55 M(+56.8%) |
| Dec 2023 | $99.96 M(+12.1%) | $26.15 M(-769.6%) | $100.47 M(-8.5%) |
| Sept 2023 | - | -$3.90 M(-130.2%) | $109.83 M(-21.5%) |
| June 2023 | - | $12.95 M(-80.2%) | $139.93 M(-6.2%) |
| Mar 2023 | - | $65.28 M(+83.8%) | $149.17 M(+67.3%) |
| Dec 2022 | $89.18 M(-37.5%) | $35.51 M(+35.6%) | $89.18 M(+0.2%) |
| Sept 2022 | - | $26.19 M(+18.1%) | $88.96 M(-6.4%) |
| June 2022 | - | $22.19 M(+319.5%) | $95.08 M(-22.9%) |
| Mar 2022 | - | $5.29 M(-85.0%) | $123.37 M(-13.6%) |
| Dec 2021 | $142.77 M(+151.9%) | $35.29 M(+9.2%) | $142.77 M(+0.6%) |
| Sept 2021 | - | $32.31 M(-36.0%) | $141.88 M(+30.4%) |
| June 2021 | - | $50.48 M(+104.5%) | $108.77 M(+12.3%) |
| Mar 2021 | - | $24.69 M(-28.2%) | $96.85 M(+70.9%) |
| Dec 2020 | $56.67 M(-93.5%) | $34.40 M(-4427.2%) | $56.67 M(+26.0%) |
| Sept 2020 | - | -$795.00 K(-102.1%) | $44.97 M(+3.5%) |
| June 2020 | - | $38.55 M(-348.9%) | $43.43 M(+1490.2%) |
| Mar 2020 | - | -$15.49 M(-168.2%) | $2.73 M(-99.7%) |
| Dec 2019 | $876.12 M(+269.0%) | $22.70 M(-1072.4%) | $876.12 M(+6.8%) |
| Sept 2019 | - | -$2.33 M(+8.9%) | $820.26 M(-10.7%) |
| June 2019 | - | -$2.14 M(-100.2%) | $918.74 M(-11.1%) |
| Mar 2019 | - | $857.90 M(-2686.9%) | $1.03 B(+335.2%) |
| Dec 2018 | $237.40 M(+186.7%) | -$33.16 M(-134.5%) | $237.40 M(-23.1%) |
| Sept 2018 | - | $96.15 M(-14.4%) | $308.79 M(+33.8%) |
| June 2018 | - | $112.34 M(+81.0%) | $230.80 M(+73.8%) |
| Mar 2018 | - | $62.07 M(+62.4%) | $132.81 M(+58.2%) |
| Dec 2017 | $82.81 M(+158.0%) | $38.23 M(+110.5%) | $83.94 M(+86.8%) |
| Sept 2017 | - | $18.16 M(+26.6%) | $44.95 M(+27.7%) |
| June 2017 | - | $14.35 M(+8.7%) | $35.18 M(+27.4%) |
| Mar 2017 | - | $13.20 M(-1836.2%) | $27.62 M(-13.9%) |
| Dec 2016 | $32.09 M(+7.1%) | -$760.00 K(-109.0%) | $32.09 M(-26.7%) |
| Sept 2016 | - | $8.40 M(+23.9%) | $43.77 M(-2.6%) |
| June 2016 | - | $6.78 M(-61.6%) | $44.96 M(+3.6%) |
| Mar 2016 | - | $17.67 M(+61.9%) | $43.40 M(+44.9%) |
| Dec 2015 | $29.96 M(+28.2%) | $10.92 M(+13.9%) | $29.95 M(+0.2%) |
| Sept 2015 | - | $9.59 M(+83.3%) | $29.89 M(+21.1%) |
| June 2015 | - | $5.23 M(+23.9%) | $24.68 M(+14.2%) |
| Mar 2015 | - | $4.22 M(-61.1%) | $21.62 M(-7.5%) |
| Dec 2014 | $23.37 M(+25.3%) | $10.86 M(+148.2%) | $23.37 M(+18.1%) |
| Sept 2014 | - | $4.38 M(+102.3%) | $19.79 M(+2.1%) |
| June 2014 | - | $2.16 M(-63.8%) | $19.38 M(-2.7%) |
| Mar 2014 | - | $5.97 M(-18.0%) | $19.93 M(+6.9%) |
| Dec 2013 | $18.65 M(+373.0%) | $7.28 M(+83.7%) | $18.64 M(+11.4%) |
| Sept 2013 | - | $3.96 M(+46.5%) | $16.74 M(+37.8%) |
| June 2013 | - | $2.71 M(-42.3%) | $12.15 M(+39.6%) |
| Mar 2013 | - | $4.69 M(-12.8%) | $8.71 M(+120.9%) |
| Dec 2012 | $3.94 M(+29.5%) | $5.38 M(-963.2%) | $3.94 M(-6.4%) |
| Sept 2012 | - | -$623.00 K(-15.7%) | $4.21 M(+0.5%) |
| June 2012 | - | -$739.00 K(+898.6%) | $4.19 M(-31.4%) |
| Mar 2012 | - | -$74.00 K(-101.3%) | $6.11 M(+99.6%) |
| Dec 2011 | $3.04 M(-123.2%) | $5.65 M(-975.8%) | $3.06 M(-175.3%) |
| Sept 2011 | - | -$645.00 K(-154.8%) | -$4.06 M(-71.3%) |
| June 2011 | - | $1.18 M(-137.7%) | -$14.18 M(-0.9%) |
| Mar 2011 | - | -$3.12 M(+111.9%) | -$14.30 M(+8.9%) |
| Dec 2010 | -$13.13 M(+103.0%) | -$1.47 M(-86.3%) | -$13.13 M(+33.3%) |
| Sept 2010 | - | -$10.76 M(-1123.7%) | -$9.85 M(-455.9%) |
| June 2010 | - | $1.05 M(-153.8%) | $2.77 M(-242.0%) |
| Mar 2010 | - | -$1.95 M(-207.8%) | -$1.95 M(-69.9%) |
| Dec 2009 | -$6.47 M | $1.81 M(-2.5%) | -$6.46 M(-92.1%) |
| Sept 2009 | - | $1.86 M(-150.7%) | -$81.46 M(-7.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$3.66 M(-43.4%) | -$88.43 M(-2.2%) |
| Mar 2009 | - | -$6.47 M(-91.2%) | -$90.40 M(-4.9%) |
| Dec 2008 | -$96.26 M(+88.7%) | -$73.19 M(+1333.1%) | -$95.08 M(+323.0%) |
| Sept 2008 | - | -$5.11 M(-9.3%) | -$22.48 M(-12.5%) |
| June 2008 | - | -$5.63 M(-49.5%) | -$25.69 M(-23.3%) |
| Mar 2008 | - | -$11.15 M(+1795.9%) | -$33.49 M(-33.6%) |
| Dec 2007 | -$51.02 M(-17.5%) | -$588.00 K(-92.9%) | -$50.47 M(-28.4%) |
| Sept 2007 | - | -$8.32 M(-38.0%) | -$70.45 M(-12.4%) |
| June 2007 | - | -$13.43 M(-52.3%) | -$80.41 M(+0.0%) |
| Mar 2007 | - | -$28.13 M(+36.8%) | -$80.41 M(+30.0%) |
| Dec 2006 | -$61.86 M(+148.2%) | -$20.57 M(+12.5%) | -$61.86 M(+3.0%) |
| Sept 2006 | - | -$18.28 M(+36.2%) | -$60.08 M(+44.3%) |
| June 2006 | - | -$13.43 M(+40.0%) | -$41.64 M(+38.8%) |
| Mar 2006 | - | -$9.59 M(-49.0%) | -$29.99 M(-5.4%) |
| Dec 2005 | -$24.92 M(>+9900.0%) | -$18.78 M(<-9900.0%) | -$31.72 M(-207.7%) |
| Sept 2005 | - | $158.00 K(-108.9%) | $29.44 M(+67.8%) |
| June 2005 | - | -$1.78 M(-84.2%) | $17.55 M(+355.0%) |
| Mar 2005 | - | -$11.31 M(-126.7%) | $3.86 M(-3773.3%) |
| Dec 2004 | -$105.00 K(-99.8%) | $42.38 M(-461.1%) | -$105.00 K(-99.9%) |
| Sept 2004 | - | -$11.74 M(-24.2%) | -$83.04 M(+9.3%) |
| June 2004 | - | -$15.48 M(+1.3%) | -$75.97 M(+15.1%) |
| Mar 2004 | - | -$15.27 M(-62.3%) | -$66.03 M(+10.6%) |
| Dec 2003 | -$59.69 M(+69.9%) | -$40.56 M(+769.8%) | -$59.69 M(+46.4%) |
| Sept 2003 | - | -$4.66 M(-15.7%) | -$40.77 M(-0.9%) |
| June 2003 | - | -$5.53 M(-38.1%) | -$41.12 M(-5.1%) |
| Mar 2003 | - | -$8.94 M(-58.7%) | -$43.34 M(+23.4%) |
| Dec 2002 | -$35.13 M(+112.1%) | -$21.64 M(+331.6%) | -$35.13 M(+138.8%) |
| Sept 2002 | - | -$5.01 M(-35.4%) | -$14.71 M(+17.3%) |
| June 2002 | - | -$7.76 M(+972.8%) | -$12.54 M(+18.1%) |
| Mar 2002 | - | -$723.00 K(-40.5%) | -$10.62 M(-35.9%) |
| Dec 2001 | -$16.56 M(-57.1%) | -$1.22 M(-57.3%) | -$16.56 M(-28.2%) |
| Sept 2001 | - | -$2.85 M(-51.1%) | -$23.07 M(-24.7%) |
| June 2001 | - | -$5.83 M(-12.6%) | -$30.66 M(-10.8%) |
| Mar 2001 | - | -$6.67 M(-13.7%) | -$34.38 M(-1.3%) |
| Dec 2000 | -$38.64 M(-28.7%) | -$7.72 M(-26.0%) | -$34.84 M(-20.4%) |
| Sept 2000 | - | -$10.44 M(+9.3%) | -$43.78 M(-1.3%) |
| June 2000 | - | -$9.55 M(+33.9%) | -$44.38 M(-8.0%) |
| Mar 2000 | - | -$7.13 M(-57.2%) | -$48.23 M(-4.9%) |
| Dec 1999 | -$54.19 M(-16.8%) | -$16.66 M(+51.0%) | -$50.70 M(-13.8%) |
| Sept 1999 | - | -$11.04 M(-17.6%) | -$58.84 M(-6.5%) |
| June 1999 | - | -$13.40 M(+39.6%) | -$62.90 M(-1.6%) |
| Mar 1999 | - | -$9.60 M(-61.3%) | -$63.90 M(-1.8%) |
| Dec 1998 | -$65.10 M(+210.0%) | -$24.80 M(+64.2%) | -$65.10 M(+64.8%) |
| Sept 1998 | - | -$15.10 M(+4.9%) | -$39.50 M(+22.7%) |
| June 1998 | - | -$14.40 M(+33.3%) | -$32.20 M(+29.3%) |
| Mar 1998 | - | -$10.80 M(-1450.0%) | -$24.90 M(+19.1%) |
| Dec 1997 | -$21.00 M(-10.6%) | $800.00 K(-110.3%) | -$20.90 M(-29.9%) |
| Sept 1997 | - | -$7.80 M(+9.9%) | -$29.80 M(+22.1%) |
| June 1997 | - | -$7.10 M(+4.4%) | -$24.40 M(-2.4%) |
| Mar 1997 | - | -$6.80 M(-16.0%) | -$25.00 M(+7.8%) |
| Dec 1996 | -$23.50 M(+10.8%) | -$8.10 M(+237.5%) | -$23.20 M(+8.9%) |
| Sept 1996 | - | -$2.40 M(-68.8%) | -$21.30 M(-17.1%) |
| June 1996 | - | -$7.70 M(+54.0%) | -$25.70 M(+104.0%) |
| Mar 1996 | - | -$5.00 M(-19.4%) | -$12.60 M(+14.5%) |
| Dec 1995 | -$21.20 M(+15.2%) | -$6.20 M(-8.8%) | -$11.00 M(+34.1%) |
| Sept 1995 | - | -$6.80 M(-225.9%) | -$8.20 M(+41.4%) |
| June 1995 | - | $5.40 M(-258.8%) | -$5.80 M(-65.1%) |
| Mar 1995 | - | -$3.40 M(0.0%) | -$16.60 M(-9.8%) |
| Dec 1994 | -$18.40 M | -$3.40 M(-22.7%) | -$18.40 M(+22.7%) |
| Sept 1994 | - | -$4.40 M(-18.5%) | -$15.00 M(+41.5%) |
| June 1994 | - | -$5.40 M(+3.8%) | -$10.60 M(+103.8%) |
| Mar 1994 | - | -$5.20 M | -$5.20 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual EBITDA year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of LGND is $99.96 M
What is the all time high annual EBITDA for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual earnings before interest, taxes, depreciation & amortization is $876.12 M
What is Ligand Pharmaceuticals Incorporated annual EBITDA year-on-year change?
Over the past year, LGND annual earnings before interest, taxes, depreciation & amortization has changed by +$10.78 M (+12.09%)
What is Ligand Pharmaceuticals Incorporated quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of LGND is $19.21 M
What is the all time high quarterly EBITDA for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly earnings before interest, taxes, depreciation & amortization is $857.90 M
What is Ligand Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
Over the past year, LGND quarterly earnings before interest, taxes, depreciation & amortization has changed by +$23.12 M (+592.01%)
What is Ligand Pharmaceuticals Incorporated TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of LGND is $112.45 M
What is the all time high TTM EBITDA for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.03 B
What is Ligand Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
Over the past year, LGND TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.61 M (+2.38%)